Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2025 09:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented...